Otsuka, Bristol-Myers can withdraw admissions in Abilify damages case
Allens 2020-03-02 4:05 pm By Cat Fredenburgh | Melbourne
Please login to bookmark Close

A judge has granted a request by Otsuka and Bristol-Myers Squibbs to withdraw admissions in proceedings brought by Generic Health seeking damages, after the generic drug maker was temporarily blocked from selling a generic version of antipsychotic Abilify in a patent dispute in which it ultimately triumphed.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au